Clinical Trials Logo

EGFR Exon 20 Mutation clinical trials

View clinical trials related to EGFR Exon 20 Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04036682 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

REZILIENT1
Start date: October 31, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.